Opinion|Videos|January 31, 2025
Switching Between BTK Inhibitors in CLL
Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease progression, drug interactions, and patient preferences, with pirtobrutinib emerging as a particularly valuable option for patients with BTK C481 mutations or those who have exhausted other BTK inhibitor (BTKi) options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors typically drive decisions to switch between BTK inhibitors: managing toxicity, addressing disease progression, or other considerations?
- How do these factors influence your decision on which therapy to switch to, either within the BTKi class or outside of it? Where does pirtobrutinib fit into this decision?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5